Celon Pharma increases the chances for a neuropsychiatric blockbuster and increases its export rates

Three active clinical programmes, including two regarding the most dynamic therapeutic area from the point of view of the next decade, which is neuropsychiatry, advanced pre-clinical development of drug candidates with innovative potential, continuation of construction of the largest Centre for Science and Research in Central and Eastern Europe together with a great financial resultRead more »

Celon Pharma on track to conquer the global antidepressant market worth between USD 2.5 and 4 billion.

International experts cooperating with the FDA have confirmed the efficacy and safety of eskatemine in treatment of unipolar, treatment-resistant depression, which might become the first cutting edge therapy for patients since the last innovation introduced 35 years ago. Celon Pharma develops this substance in two indications and is currently conducting phase II clinical trials. OnRead more »

Maciej Wieczorek on the strategies of developing innovative medicines at the 11th Multiciplinary conference on pharmaeutical science “Science for the Industry, Industry for science”

On 16 November this year,  President of the Management Board of Celon Pharma S.A. will give a lecture discussing the discovery and implementation of innovations in the pharmaceutical sector on the example of drug candidates developed under Celon Pharma’s clinical programmes. He will also participate in an expert debate entitled: “Business for science”. We encourageRead more »

Celon Pharma on the development of cancer drugs at the ORTC-NCI-AACR SYMPOSIUM

Aleksandra Stańczak, PhD, Leader of the Oncology Research Group will present results for two inhibitors under Celon Pharma’s development at the 30th symposium organised by European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and  American Association for Cancer Research (AACR), to be held on 13-16. November in Dublin. The followingRead more »

Celon Pharma S.A. initiates clinical development of its own cutting edge anti-cancer drug – an FGFR inhibitor

The Company’s anti-cancer drug – (CPL304110) – might be indicated for patients with lung, bladder and stomach tumours which have genetic aberrations of FGFR kinases. The objective of the trial will be to determine the drug’s safety profile (including MTD) and observation of early symptoms of drug activity in the trial subjects. The clinical trialRead more »

Celon Pharma at ESMO 2018

Representatives of the Oncology Research Group will take part in ESMO 2018, a congress organised by the European Society for Medical Oncology, which will be held on 19 October in Munich. In the course of the congress, they will present selected results of preclinical trials for the FGFR inhibitor at a poster session held onRead more »

The first stage of building Celon Pharma’s R&D Centre in Kazuń Nowy is on the home run and in line with the Company’s investment plan

Conclusion of the building shell stage was celebrated with symbolic topping out, which was carried out by representatives of Celon Pharma S.A. and  Skanska, the General Contractor, on 15 October.  The task commissioned by Celon Pharma includes general contracting of the building shell together with internal installation systems, roads and external area, as well asRead more »